Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid

A meta-analysis

Research output: Contribution to journalArticle

217 Citations (Scopus)

Abstract

BACKGROUND. Numerous studies have investigated the clinical significance of BRAF mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on the usefulness of BRAF mutation as a prognostic marker of PTC. To address this controversy, the frequency of the BRAF mutation and the associations between BRAF mutation and clinicopathologic parameters in PTC were evaluated by meta-analysis. METHODS. The relevant published studies were reviewed according to the defined selection criteria. The effect sizes of outcome parameters were estimated by odds ratio or weighted mean difference. RESULTS. The current meta-analysis included 12 studies with a total of 1168 patients. The frequency of the BRAF mutation was 49%. The BRAF mutation was associated with histologic subtype, the presence of extrathyroidal extension, and higher clinical stage, but not with age, sex, race, or tumor size. CONCLUSIONS. The effect of the BRAF mutation on the poor prognosis of PTC patients was evident from the current meta-analysis. The detection of the BRAF mutation may be used as an important prognostic marker of patients with PTC.

Original languageEnglish
Pages (from-to)38-46
Number of pages9
JournalCancer
Volume110
Issue number1
DOIs
Publication statusPublished - 2007 Jul 1

Fingerprint

Meta-Analysis
Mutation
Mutation Rate
Patient Selection
Papillary Thyroid cancer
Odds Ratio
Neoplasms

Keywords

  • BRAF
  • Meta-analysis
  • Papillary carcinoma
  • Thyroid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{f0ce2e63e5b744c0ab5a7cd8d5426832,
title = "Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: A meta-analysis",
abstract = "BACKGROUND. Numerous studies have investigated the clinical significance of BRAF mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on the usefulness of BRAF mutation as a prognostic marker of PTC. To address this controversy, the frequency of the BRAF mutation and the associations between BRAF mutation and clinicopathologic parameters in PTC were evaluated by meta-analysis. METHODS. The relevant published studies were reviewed according to the defined selection criteria. The effect sizes of outcome parameters were estimated by odds ratio or weighted mean difference. RESULTS. The current meta-analysis included 12 studies with a total of 1168 patients. The frequency of the BRAF mutation was 49{\%}. The BRAF mutation was associated with histologic subtype, the presence of extrathyroidal extension, and higher clinical stage, but not with age, sex, race, or tumor size. CONCLUSIONS. The effect of the BRAF mutation on the poor prognosis of PTC patients was evident from the current meta-analysis. The detection of the BRAF mutation may be used as an important prognostic marker of patients with PTC.",
keywords = "BRAF, Meta-analysis, Papillary carcinoma, Thyroid",
author = "Ju-Han Lee and Lee, {Eung Seok} and Kim, {Young Sik}",
year = "2007",
month = "7",
day = "1",
doi = "10.1002/cncr.22754",
language = "English",
volume = "110",
pages = "38--46",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid

T2 - A meta-analysis

AU - Lee, Ju-Han

AU - Lee, Eung Seok

AU - Kim, Young Sik

PY - 2007/7/1

Y1 - 2007/7/1

N2 - BACKGROUND. Numerous studies have investigated the clinical significance of BRAF mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on the usefulness of BRAF mutation as a prognostic marker of PTC. To address this controversy, the frequency of the BRAF mutation and the associations between BRAF mutation and clinicopathologic parameters in PTC were evaluated by meta-analysis. METHODS. The relevant published studies were reviewed according to the defined selection criteria. The effect sizes of outcome parameters were estimated by odds ratio or weighted mean difference. RESULTS. The current meta-analysis included 12 studies with a total of 1168 patients. The frequency of the BRAF mutation was 49%. The BRAF mutation was associated with histologic subtype, the presence of extrathyroidal extension, and higher clinical stage, but not with age, sex, race, or tumor size. CONCLUSIONS. The effect of the BRAF mutation on the poor prognosis of PTC patients was evident from the current meta-analysis. The detection of the BRAF mutation may be used as an important prognostic marker of patients with PTC.

AB - BACKGROUND. Numerous studies have investigated the clinical significance of BRAF mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on the usefulness of BRAF mutation as a prognostic marker of PTC. To address this controversy, the frequency of the BRAF mutation and the associations between BRAF mutation and clinicopathologic parameters in PTC were evaluated by meta-analysis. METHODS. The relevant published studies were reviewed according to the defined selection criteria. The effect sizes of outcome parameters were estimated by odds ratio or weighted mean difference. RESULTS. The current meta-analysis included 12 studies with a total of 1168 patients. The frequency of the BRAF mutation was 49%. The BRAF mutation was associated with histologic subtype, the presence of extrathyroidal extension, and higher clinical stage, but not with age, sex, race, or tumor size. CONCLUSIONS. The effect of the BRAF mutation on the poor prognosis of PTC patients was evident from the current meta-analysis. The detection of the BRAF mutation may be used as an important prognostic marker of patients with PTC.

KW - BRAF

KW - Meta-analysis

KW - Papillary carcinoma

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=34250893789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250893789&partnerID=8YFLogxK

U2 - 10.1002/cncr.22754

DO - 10.1002/cncr.22754

M3 - Article

VL - 110

SP - 38

EP - 46

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -